PATHOLOGICAPub Date : 2023-02-01DOI: 10.32074/1591-951X-840
Ferran Algaba, Gabriella Nesi
{"title":"Brief history of the who blue books on urinary and male genital tumours.","authors":"Ferran Algaba, Gabriella Nesi","doi":"10.32074/1591-951X-840","DOIUrl":"https://doi.org/10.32074/1591-951X-840","url":null,"abstract":"","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 1","pages":"1-2"},"PeriodicalIF":3.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9099153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PATHOLOGICAPub Date : 2022-12-01DOI: 10.32074/1591-951X-828
Viscardo Paolo Fabbri, Chiara Caporalini, Sofia Asioli, Annamaria Buccoliero
{"title":"Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome.","authors":"Viscardo Paolo Fabbri, Chiara Caporalini, Sofia Asioli, Annamaria Buccoliero","doi":"10.32074/1591-951X-828","DOIUrl":"10.32074/1591-951X-828","url":null,"abstract":"<p><p>The WHO 2021 classification of central nervous system cancers distinguishes diffuse gliomas that arise in adults (referred to as the \"adult type\") and those that arise in children (defined as \"paediatric\") based on clinical and molecular characteristics.\"). However, paediatric-type gliomas may occasionally be present in younger adults and occasionally adult-type gliomas may occur in children. Diffuse low-grade paediatric glioma includes diffuse astrocytoma altered by MYB or MYBL1, low-grade polymorphic juvenile neuroepithelial tumour, angiocentric glioma, and diffuse low-grade glioma with an altered MAPK pathway. Here, we examine these newly recognised entities according to WHO diagnostic criteria and propose an integrated diagnostic approach that can be used to separate these clinically and biologically distinct tumor groups.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"410-421"},"PeriodicalIF":4.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/93/pathol-2022-06-410.PMC9763978.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10475234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Newly recognised Tumour Types in Glioneuronal tumours according to the 5th edition of the CNS WHO Classification.","authors":"Valeria Barresi, Francesca Gianno, Gianluca Marucci","doi":"10.32074/1591-951X-819","DOIUrl":"https://doi.org/10.32074/1591-951X-819","url":null,"abstract":"<p><p>Glioneuronal tumours (GNT) are uncommon neoplasms, characterised by glial and neuronal differentiation.</p><p><p>In the 5th edition of the World Health Organization (WHO) Classification, they are grouped under the heading \"Glioneuronal and neuronal tumours\", which comprises fourteen different tumours, among which the diffuse glioneuronal tumour with oligodendroglioma-like cells and nuclear clusters (DGONC), myxoyd glioneuronal tumour (MGT) and multinodular and vacuolating neuronal tumour (MNVNT) are new types.</p><p><p>MGT and MNVNT are classified WHO grade 1 and may be recognised and diagnosed by peculiar clinical-pathological features. DGONC was not assigned a WHO grade and was only provisionally included among GNT, due to the possibility that it rather represents an embryonal tumour type or subtype. Although the histopathological characteristics may be useful for its identification, the specific methylation profile is an essential diagnostic criterion for DGONC.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"447-454"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/4f/pathol-2022-06-447.PMC9763980.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ependymomas.","authors":"Luca Bertero, Alessia Andrea Ricci, Cristian Tampieri, Paola Cassoni, Piergiorgio Modena","doi":"10.32074/1591-951X-817","DOIUrl":"https://doi.org/10.32074/1591-951X-817","url":null,"abstract":"<p><p>Ependymal neoplasms are a heterogenous group of neoplasms arising from the progenitors of the cells lining the ventricular system and the spinal central canal. During the last few years, significant novel data concerning oncogenesis, molecular characteristics and clinical correlations of these tumours have been collected, with a strong relevance for their pathological classification. The recently published 5th edition of WHO Classification of Central Nervous System Tumours integrates this novel knowledge and represents a substantial update compared to the previous edition. Concerning supratentorial ependymomas, the previous <i>RELA</i> fusion-positive ependymoma has been renamed into <i>ZFTA</i> fusion-positive and the novel <i>YAP1</i> fusion-positive ependymoma subtype has been added. Posterior fossa ependymomas should now be allocated either to the Type A or Type B subtypes based on molecular profiling or using the H3 K27me3 immunohistochemical surrogate. Regarding spinal ependymomas, a novel subtype has been added based on a distinctive molecular trait, presence of <i>MYCN</i> amplification, and on the unfavourable outcome. Finally, myxopapillary ependymoma is now classified as a grade 2 tumour in accordance with its overall prognosis which mirrors that of conventional spinal ependymomas. The aim of this review is to present these changes and summarize the current diagnostic framework of ependymal tumours, according to the most recent updates.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"436-446"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/2a/pathol-2022-06-436.PMC9763977.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PATHOLOGICAPub Date : 2022-12-01DOI: 10.32074/1591-951X-823
Manila Antonelli, Pietro Luigi Poliani
{"title":"Adult type diffuse gliomas in the new 2021 WHO Classification.","authors":"Manila Antonelli, Pietro Luigi Poliani","doi":"10.32074/1591-951X-823","DOIUrl":"https://doi.org/10.32074/1591-951X-823","url":null,"abstract":"<p><p>Adult-type diffuse gliomas represent a group of highly infiltrative central nervous system tumors with a prognosis that significantly varies depending on the specific subtype and histological grade. Traditionally, adult-type diffuse gliomas have been classified based on their morphological features with a great interobserver variability and discrepancy in patient survival even within the same histological grade. Over the last few decades, advances in molecular profiling have drastically changed the diagnostic approach and classification of brain tumors leading to the development of an integrated morphological and molecular classification endowed with a more clinically relevant value. These concepts were largely anticipated in the revised fourth-edition of WHO classification of central nervous system tumors published in 2016. The fifth-edition (WHO 2021) moved molecular diagnostics forward into a full integration of molecular parameters with the histological features into an integrative diagnostic approach. Diagnosis of adult type diffuse gliomas, IDH mutant and IDH-wildtype has been simplified by introducing revised diagnostic and grading criteria. In this review, we will discuss the most recent updates to the classification of adult-type diffuse gliomas and summarize the essential diagnostic keys providing a practical guidance to pathologists.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"397-409"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/41/pathol-2022-06-397.PMC9763975.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PATHOLOGICAPub Date : 2022-12-01DOI: 10.32074/1591-951X-826
Cristina Pizzimenti, Francesca Gianno, Marco Gessi
{"title":"Expanding the spectrum of \"mesenchymal\" tumors of the central nervous system.","authors":"Cristina Pizzimenti, Francesca Gianno, Marco Gessi","doi":"10.32074/1591-951X-826","DOIUrl":"https://doi.org/10.32074/1591-951X-826","url":null,"abstract":"<p><p>In this review, we summarize the clinical, histopathological, and molecular features of central nervous system (CNS) tumors with <i>BCOR</i> internal tandem duplication, intracranial mesenchymal tumor with <i>FET/CREB</i> fusion, CNS <i>CIC-</i>rearranged sarcomas and primary intracranial sarcoma <i>DICER1</i>-mutant, now included in the 2021 WHO classification of CNS tumors. Possible relationships between tumors occurring in the CNS and their systemic counterparts are discussed.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"455-464"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/0c/pathol-2022-06-455.PMC9763981.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PATHOLOGICAPub Date : 2022-12-01DOI: 10.32074/1591-951X-839
Mattia Barbareschi, Marco Gessi, Felice Giangaspero
{"title":"Introduction.","authors":"Mattia Barbareschi, Marco Gessi, Felice Giangaspero","doi":"10.32074/1591-951X-839","DOIUrl":"https://doi.org/10.32074/1591-951X-839","url":null,"abstract":"This is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons. org/licenses/by-nc-nd/4.0/deed.en PATHOLOGICA 2022;114:395-396; DOI: 10.32074/1591-951X-839","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"395-396"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/75/3c/pathol-2022-06-395.PMC9763976.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9113084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PATHOLOGICAPub Date : 2022-12-01DOI: 10.32074/1591-951X-830
Francesca Gianno, Isabella Giovannoni, Barbara Cafferata, Francesca Diomedi-Camassei, Simone Minasi, Sabina Barresi, Francesca Romana Buttarelli, Viola Alesi, Antonello Cardoni, Manila Antonelli, Chiara Puggioni, Giovanna Stefania Colafati, Andrea Carai, Maria Vinci, Angela Mastronuzzi, Evelina Miele, Rita Alaggio, Felice Giangaspero, Sabrina Rossi
{"title":"Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.","authors":"Francesca Gianno, Isabella Giovannoni, Barbara Cafferata, Francesca Diomedi-Camassei, Simone Minasi, Sabina Barresi, Francesca Romana Buttarelli, Viola Alesi, Antonello Cardoni, Manila Antonelli, Chiara Puggioni, Giovanna Stefania Colafati, Andrea Carai, Maria Vinci, Angela Mastronuzzi, Evelina Miele, Rita Alaggio, Felice Giangaspero, Sabrina Rossi","doi":"10.32074/1591-951X-830","DOIUrl":"10.32074/1591-951X-830","url":null,"abstract":"<p><p>As a relevant element of novelty, the fifth CNS WHO Classification highlights the distinctive pathobiology underlying gliomas arising primarily in children by recognizing for the first time the families of paediatric-type diffuse gliomas, both high-grade and low-grade. This review will focus on the family of paediatric-type diffuse high-grade gliomas, which includes four tumour types: 1) Diffuse midline glioma H3 K27-altered; 2) Diffuse hemispheric glioma H3 G34-mutant; 3) Diffuse paediatric-type high-grade glioma H3-wildtype and IDH-wildtype; and 4) Infant-type hemispheric glioma. The essential and desirable diagnostic criteria as well as the entities entering in the differential will be discussed for each tumour type. A special focus will be given on the issues encountered in the daily practice, especially regarding the diagnosis of the diffuse paediatric-type high-grade glioma H3-wildtype and IDH-wildtype. The advantages and the limits of the multiple molecular tests which may be utilised to define the entities of this tumour family will be evaluated in each diagnostic context.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"422-435"},"PeriodicalIF":4.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/77/pathol-2022-06-422.PMC9763979.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PATHOLOGICAPub Date : 2022-10-01DOI: 10.32074/1591-951X-809
Iteeka Arora, Nandita Gupta, M Angeles Montero, Patrizia Viola
{"title":"Pulmonary mixed squamous and glandular papilloma: diagnostic challenges of a rare lesion when the clock is ticking. How to avoid interpretation mistakes.","authors":"Iteeka Arora, Nandita Gupta, M Angeles Montero, Patrizia Viola","doi":"10.32074/1591-951X-809","DOIUrl":"https://doi.org/10.32074/1591-951X-809","url":null,"abstract":"<p><p>Pulmonary mixed squamous and glandular papillomas (MSCGPs) are rare, benign neoplasms with peculiar clinical and histological features. However, on occasion, they can present certain characteristics that overlap with other neoplasms including carcinomas. Recognising these features is hence important for treatment purposes. Molecular studies can sometimes help in further characterisation, although they should not guide the diagnosis which ultimately relies on morphology.</p><p><p>We report a challenging case of MSCGP with unusual features, received during intraoperative consultation. We highlight the subtle morphological features to help avoid overcalling a benign lesion as malignant.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 5","pages":"391-394"},"PeriodicalIF":3.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/b0/pathol-2022-05-391.PMC9614298.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40455107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application.","authors":"Luca Mastracci, Federica Grillo, Paola Parente, Irene Gullo, Michela Campora, Valentina Angerilli, Chiara Rossi, Maria Luisa Sacramento, Gianmaria Pennelli, Alessandro Vanoli, Matteo Fassan","doi":"10.32074/1591-951X-803","DOIUrl":"https://doi.org/10.32074/1591-951X-803","url":null,"abstract":"<p><p>Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predictive value of PD-L1 as an immunohistochemical biomarker has been extensively studied in gastrointestinal neoplasms. Until now, its predictive value has been demonstrated, and is currently in use only in upper gastrointestinal malignancies (gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma).</p><p><p>In this Review, we describe the technical aspects and challenges related to PD-L1 immunohistochemical assays, the current role of PD-L1 as a biomarker in clinical practice and we outline the main studies and clinical trials analyzing the prognostic and predictive value of PD-L1 in gastrointestinal cancers.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 5","pages":"352-364"},"PeriodicalIF":3.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/c8/pathol-2022-05-352.PMC9614301.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40434351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}